Multiomic Health partners with Alloy Therapeutics, Inc. to develop first-in-class renal tissue-targeting drugs. MultiOmic Health contributes its AI-enabled precision medicine discovery platform and expertise in kidney disease biology to the partnership. Alloy has developed an impressive bispecific antibody and genetic medicine platform. “We are excited to partner with Alloy, a well-known industry player with leading-edge drug molecule engineering platforms that have been the basis of 10 clinical-stage assets so far, including two in Phase II trials,” said Robert Thong, MultiOmic Health’s CEO and Co-Founder. Precision medicines for chronic renal conditions targeted to the kidney tissue of specific patient subpopulations are expected to display an order of magnitude improvement in efficacy and safety, compared to conventional systemic drugs aimed at all patients diagnosed with those conditions. Press release: https://lnkd.in/dcxE5sA6
